Immorta Bio Doubles Mouse Lifespan Using Combination Senolytic and Regenerative Therapy in Validated Aging Models

Scientific Longevity Company to Present New Breakthrough Data at J.P. Morgan–Affiliated Biotech Showcase 2026

MIAMI and SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Immorta Bio Inc., a scientific longevity company dedicated to Treating Diseases of Aging and Treating Aging as Disease™, today announced new data demonstrating that its combination therapy of SenoVax™, a first-in-class senolytic immunotherapy, and personalized mesenchymal stem cells (pMSCs) from its breakthrough StemCellRevivify™ platform, doubled lifespan and significantly extended healthspan in validated murine aging models.